本帖最后由 老马 于 2013-3-13 13:43 编辑 ) f. h, S3 P5 k" F1 i# P
7 X( W1 X( F4 J0 J9 m# G健择(吉西他滨)+顺铂+阿瓦斯汀. i7 x/ @1 s, s8 C& u
Gemzar +Cisplatin + Avastin$ v6 d/ g( p' q
http://annonc.oxfordjournals.org/content/21/9/1804.full$ y: ^0 s2 S/ X0 V. v$ A3 W7 i
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 5 H* v. ]! S" X# z0 u4 [) x
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ' C0 A* z1 T" k& U
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
8 E. S. b$ l& e0 @ G
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 614)
3 C4 \* N: i8 Z
华为网盘附件:
- C/ e$ w7 a1 a/ l4 |+ }【华为网盘】ava.JPG
. E8 ^! G( J# n+ } |